Literature DB >> 21991048

Severe bullous skin diseases: analysis of seven children managed in a burns unit.

S Elkharaz1, E M Abdel-Razek, A Eldin, A M Abdel-Razek.   

Abstract

Patients suffering from considerable cutaneous loss must be treated under strict aseptic conditions and with positive pressure ventilation, which is available in burns units. The differentiation of severe bullous skin diseases remains a challenge for the clinician. We report seven cases of severe bullous skin diseases in a paediatric age group treated in a burns unit with the cooperation of a paediatric intensive care unit (King Saud Hospital, Unizah, Kingdom of Saudia Arabia) between 2001 and 2005. Toxic epidermal necrolysis (Lyell's syndrome) was encountered in five cases, staphylococcal scalded-skin syndrome in one, and generalized drug eruption in one. The mortality rate was 14% (one of the seven patients). Most of the children presented with about 35% desquamation and 45% intact bullous formation (70-80% total body surface area involvement). The majority presented after the sudden onset of high fever, signs of systemic toxicity, and intense mucocutaneous exfoliation. The diagnosis was confirmed by skin biopsy and culture swabs. All the patients were managed as for mixed second-degree burns with regard to fluid calculation and hydrotherapy. We used the closed technique for dressing. The results are presented, and the literature was searched for similar cases reported in other parts of the world. The importance of diagnosis and appropriate treatment of the condition is emphasized.

Entities:  

Keywords:  ANALYSIS; BULLOUS; BURNS; CHILDREN; DISEASES; MANAGED; SEVEN; SEVERE; SKIN; UNIT

Year:  2006        PMID: 21991048      PMCID: PMC3188110     

Source DB:  PubMed          Journal:  Ann Burns Fire Disasters        ISSN: 1592-9558


  20 in total

1.  Steven Johnson syndrome due to I.V Ceftriaxone--a case report.

Authors:  Veena S Narayanan; G P Mamatha; L Ashok; Nadig Rajashekar
Journal:  Indian J Dent Res       Date:  2003 Oct-Dec

2.  Toxic epidermal necrolysis: a burn-centre challenge.

Authors:  W Peters; J Zaidi; L Douglas
Journal:  CMAJ       Date:  1991-06-01       Impact factor: 8.262

3.  Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.

Authors:  P H Halebian; V J Corder; M R Madden; J L Finklestein; G T Shires
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

4.  The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.

Authors:  H L Chan; R S Stern; K A Arndt; J Langlois; S S Jick; H Jick; A M Walker
Journal:  Arch Dermatol       Date:  1990-01

5.  Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins.

Authors:  P Paquet; E Jacob; P Damas; G E Piérard
Journal:  Burns       Date:  2001-09       Impact factor: 2.744

6.  Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center.

Authors:  T McGee; A Munster
Journal:  Plast Reconstr Surg       Date:  1998-09       Impact factor: 4.730

7.  Experience with toxic epidermal necrolysis treated in a burn center.

Authors:  D R Yarbrough
Journal:  J Burn Care Rehabil       Date:  1996 Jan-Feb

8.  Burn center care for patients with toxic epidermal necrolysis.

Authors:  J J Kelemen; W G Cioffi; W F McManus; A D Mason; B A Pruitt
Journal:  J Am Coll Surg       Date:  1995-03       Impact factor: 6.113

9.  Toxic epidermal necrolysis in patients receiving anticonvulsants and cranial irradiation: a risk to consider.

Authors:  David Aguiar; Roberto Pazo; Ignacio Durán; Josefa Terrasa; Antonio Arrivi; Herminio Manzano; Javier Martín; Julio Rifá
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

10.  Cost of medications in patients admitted to a burn center.

Authors:  Patricia Cornish; Nicole Mittmann; Manuel Gomez; Robert C Cartotto; Joel S Fish
Journal:  Am J Clin Dermatol       Date:  2003       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.